Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01736254 · ClinicalTrials.gov registry record · Phase 1
A Study of Evacetrapib in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01736254 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 24 participants.
The verdict
NCT01736254, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether concentrations of the study drug (evacetrapib) in the blood stream is the same or is different when the person is also taking gemfibrozil (a drug used to lower lipid levels). Each participant will receive gemfibrozil alone, evacetrapib alone, and both drugs in combination. There is no washout period between doses. The safety of both of the study drugs given together will be evaluated. Information about any side effects that may have occurred will also be collected. This study will last approximately 36 days.
Interventions
- DRUG Evacetrapib
- DRUG Gemfibrozil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2012-12 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01736254
The ClinicalTrials.gov registry entry for NCT01736254 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Evacetrapib is the first listed.
NCT01736254 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01736254 about?
NCT01736254 is a clinical study titled "A Study of Evacetrapib in Healthy Participants". The purpose of this study is to determine whether concentrations of the study drug (evacetrapib) in the blood stream is the same or is different when the person is also taking gemfibrozil (a drug used to lower lipid levels). Each participant will receive gemfibrozil alone, evacetrapib alone, and bot...
What is the current status of trial NCT01736254?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2012-12. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01736254?
The interventions under investigation include: Evacetrapib (DRUG), Gemfibrozil (DRUG).
Who is sponsoring clinical trial NCT01736254?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.